All In Biotech

Drug Trial Radar · NCT01186861

Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

A Randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Erlotinib Plus Placebo in Patients With Nonprogression Following Four Cycles of 1st-line Platinum-based Chemotherapy for Advanced NSCLC

Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 205 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

205

Actual

Start

Mar 4, 2011

Primary completion

Jul 1, 2013

Study completion Mar 11, 2015

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Aug 23, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, double-blind, placebo-controlled, phase 2 study with a 1:1 randomization scheme.

Conditions

  • Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Interventions

  • OSI-906Drug

    Tablet administered with food and with up to 200 mL of water

  • erlotinibDrug

    Tablet administered at least 2 hours after food with up to 200 mL of water

  • placeboDrug

    Tablet administered at least 2 hours after food with up to 200 mL of water

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Progression Free Survival (PFS) of maintenance OSI-906 plus erlotinib, or placebo plus erlotinib in patients with nonprogression following four cycles of first-line platinum-based chemotherapy for advanced NSCLC in the overall populationTime frame: 22 months

Locations

69 sites in 9 countries. Site status is shown where the registry gives one.

  • Site US10007

    Jacksonville, Florida

  • Site US10001

    Port Saint Lucie, Florida

  • Site US10002

    Albany, Georgia

  • Site US10008

    Chicago, Illinois

  • Site US10011

    Scarborough, Maine

  • Site US10004

    Greensboro, North Carolina

  • Site US10010

    Winston-Salem, North Carolina

  • Site BR55005

    Barretos, Brazil

  • Site BR55004

    Brasília, Brazil

  • Site BR55015

    Cachoeiro de Itapemirim, Brazil

  • Site BR55011

    Florianópolis, Brazil

  • Site BR55003

    Fortaleza, Brazil

  • Site BR55016

    Goiânia, Brazil

  • Site BR55006

    Ijuí, Brazil

  • Site BR55001

    Itajaí, Brazil

  • Site BR55008

    Piracicaba, Brazil

  • Site BR55013

    Porto Alegre, Brazil

  • Site BR55014

    Porto Alegre, Brazil

  • Site BR55012

    Ribeirão Preto, Brazil

  • Site BR55002

    Rio de Janeiro, Brazil

  • Site BR55007

    São Paulo, Brazil

  • Site CA11001

    Oshawa, Canada

  • Site CA11004

    Ottawa, Canada

  • Site CA11006

    Toronto, Canada

  • Site CA11002

    Toronto, Canada

  • Site DE49014

    Berlin, Germany

  • Site DE49008

    Cologne, Germany

  • Site DE49011

    Dortmund, Germany

  • Site DE49003

    Großhansdorf, Germany

  • Site DE49001

    Heidelberg, Germany

  • Site DE49002

    Hemer, Germany

  • Site DE49009

    Homburg/Saar, Germany

  • Site DE49006

    Immenhausen, Germany

  • Site DE49012

    Karlsruhe, Germany

  • Site DE49015

    Kassel, Germany

  • Site DE49010

    Lübeck, Germany

  • Site DE49013

    Mainz, Germany

  • Site DE49005

    Minden, Germany

  • Site PL48002

    Elblag, Poland

  • Site PL48005

    Szczecin, Poland

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.